AMSBIO Launches Animal-Free and Endotoxin-Free Stem Cell Factors
A new range of animal-free and endotoxin-free growth factors and cytokines, tailored to stem cell research, has been launched by AMSBIO — a leading supplier of recombinant proteins.
The success of stem cell research depends on the development of optimal cell culture systems. Both expansion and differentiation of stem cells is highly reliant on growth factor and cytokine supplements, with the activity and purity of these recombinants being critical to successful research and clinical applications. Despite recognised limitations, E. coli and mammalian cells remain the dominant expression systems for commercial recombinant protein production. Although significant improvements in manufacture have been made, both systems present a risk of unwanted contamination from pathogens and endotoxins.
Endotoxins are an unavoidable by-product of commercial E.coli recombinant protein manufacture, including those produced for stem cell research. The stability of endotoxins and affinity for proteins make it almost impossible to completely remove endotoxins. As a result the currently accepted safety limit of endotoxin impurities in recombinant protein products is below < 0.1 ng/µg endotoxin or 1 EU/mg. Although pathogen risks are well documented, there are a growing number of reports that demonstrate endotoxin concentrations as low as 2 pg/mL can result in significant biological responses.
To address the growing body of evidence suggesting accepted levels of endotoxin contamination may significantly compromise stem cell maintenance and differentiation, AMSBIO has launched its new range of animal-free and endotoxin-free growth factors and cytokines. These new recombinant growth factors and cytokines are produced in a plant based expression system that utilises barley seed to eliminate the risks and limitations associated with these traditional expression systems.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance